Ophthalmology Times Europe

Guess what? Ophthalmology Times Europe wants to hear from you. We want you to get the most out of the insights our editorial team and clinician contributors bring to every issue, in print and online. Help us shape the future of our content by telling us what you'd like to see more of! Cast your vote in the poll below. If you have additional ideas or favorite pieces already on our website that you'd like to see more of share them in the comments! We appreciate your participation. #ophthalmology #refractivesurgery #paediatriceyecare #retinacare #glaucoma #cornea #oculartherapies

Do you subscribe to our print issue? If not, consider this our end-of-year gift to you. This edition of The Look includes digital versions of our 2024 cover stories. Details of innovative therapies in glaucoma and cornea care, a close look at gender equity within ophthalmology, complex case studies with plenty of clinical pearls...Yep, this is the gift that keeps on giving.

Explore our newest Case of the Month featuring Liem Trinh, MD, an ophthalmologist at the Quinze-Vingts National Ophthalmology Hospital in Paris, France. Hear his perspective on the latest hydrophobic trifocal intraocular lens (IOL) and microscopes from ZEISS. Discover the benefits of these technologies, from imrpoved surgical visualization to fine-tuning of the surgical view. Read the full article: https://ow.ly/Yj1y50UfgKY #IntraocularLens #Microscopes #ZEISS

Explore our newest Case of the Month featuring Liem Trinh, MD, an ophthalmologist at the Quinze-Vingts National Ophthalmology Hospital in Paris, France. Hear his perspective on the latest hydrophobic trifocal intraocular lens (IOL) and microscopes from ZEISS. Discover the benefits of these technologies, from imrpoved surgical visualization to fine-tuning of the surgical view. Read the full article: https://ow.ly/Yj1y50UfgKY #IntraocularLens #Microscopes #ZEISS

This Thanksgiving, we’re thankful for you—the ophthalmology community driving innovation and improving lives. Wishing you and your loved ones a joyful holiday! 🍁

🚨 November Issue Alert! 🚨 The latest edition of Ophthalmology Times Europe is out now. Stay ahead with the latest research and insights in the field of ophthalmology. Access the November 2024 issue here: https://ow.ly/jcE750UgXv8 #NewIssue #Ophthalmology

Explore our newest Case of the Month featuring Liem Trinh, MD, an ophthalmologist at the Quinze-Vingts National Ophthalmology Hospital in Paris, France. Hear his perspective on the latest hydrophobic trifocal intraocular lens (IOL) and microscopes from ZEISS. Discover the benefits of these technologies, from imrpoved surgical visualization to fine-tuning of the surgical view. Read the full article: https://ow.ly/Yj1y50UfgKY #IntraocularLens #Microscopes #ZEISS

Oh, wow—you've got The Look! We are so excited to share the first edition of The look, our LinkedIn newsletter, with you today. Each month, Ophthalmology Times Europe will highlight a different topic in the eye care space. As you likely know, November is diabetes awareness month, and it's especially important for eye care providers to be attuned to the ocular aspects of the disease. We've curated recent news, valuable research findings and expert commentary in diabetic eye care to make sure you have all you need to serve your patients.

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. It has been approved for use in adult patients for the treatment of neovascular (wet) age related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (RVO; branch or central RVO), visual impairment due to diabetic macular oedema (DME), and visual impairment due to myopic choroidal neovascularisation (myopic CNV), according to a press release from Samsung Bioepis. https://lnkd.in/dWQExUfq

The FDA comments in the CRL were not related to safety or efficacy, but a statistical matter pertaining to proposed labelling language for the product. https://lnkd.in/e9AZjTay